Teva Pharmaceutical Industries (NYSE:TEVA – Free Report) had its price target raised by UBS Group from $28.00 to $30.00 in a research note published on Thursday,Benzinga reports. UBS Group currently ...

Teva Pharmaceutical Industries Limited ( NYSE: TEVA) 43rd Annual J.P. Morgan Healthcare Conference January 13, 2025 11:15 AM ET Richard Francis - President and CEO Eric Hughes - Head of R&D and Chief ...

Teva Pharmaceutical Industries Ltd (TEVA) stock saw a decline, ending the day at $20.44 which represents a decrease of $-0.50 or -2.39% from the prior close of $20.94. The stock opened at $20.95 and ...

Teva Pharmaceutical Industries sues CMS over Medicare drug pricing negotiations policy, claiming agency has unchecked ...

Bank of America Securities analyst Jason Gerberry has reiterated their bullish stance on TEVA stock, giving a Buy rating on January 21.Invest ...

Diversify Advisory Services LLC raised its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA – Free Report) by 2.5% during the fourth quarter, according to its most recent ...

The Delaware Supreme Court affirmed Friday a trial court’s decision in favor of Teva Pharmaceutical Industries Ltd.'s US unit ...

In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a ...

Teva Pharmaceutical Industries (NYSE:TEVA), a global leader in generic and specialty medicines with a market capitalization of $24.6 billion, has been navigating a complex landscape of legal ...

Pharmaceutical companies brace for the upcoming Trump administration. Teva Pharmaceuticals (TEVA) CEO Richard Francis joins ...

Teva Pharmaceuticals (TEVA) CEO Richard Francis joins Seana Smith and Madison Mills on Catalysts to discuss what both the pharmaceutical company and industry at large are expecting from Trump's ...

Teva Pharmaceuticals challenges the Inflation Reduction Act, arguing CMS's drug pricing policies harm generics, biosimilars, ...